Articles from Distalmotion

Lausanne, Switzerland, April 01, 2026 (GLOBE NEWSWIRE) -- Distalmotion, the global MedTech company expanding access to robotic surgery in outpatient sites of care, announced that it submitted a 510(k) application to the US Food and Drug Administration (FDA) in March to seek clearance for sacrocolpopexy, sacrocervicopexy, and endometriosis resection for the DEXTER® Robotic Surgery System in the US.

Lausanne, Switzerland, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Distalmotion, the global MedTech company empowering access to robotic surgery in outpatient sites of care, today announced a strategic investment from Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc (“JJDC”).

Lausanne, Switzerland, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Distalmotion, the global MedTech company empowering access to the benefits of robotic surgery in outpatient sites of care, today announced the successful closing of its Series G financing round. The $150M USD financing was led by Revival Healthcare Capital and included inside investor participation.

Lausanne, Switzerland, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Distalmotion, the global MedTech company empowering access to the benefits of robotic surgery in outpatient sites of care, today announced that it has received FDA 510(k) clearance for the use of its DEXTER® Robotic Surgery System in total benign hysterectomy as well as oophorectomy, salpingectomy, and other gynecologic procedures. This milestone marks the company’s third approved indication in the United States, following prior FDA clearances for inguinal hernia repair and cholecystectomy.

Lausanne, Switzerland, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Distalmotion today announced continued momentum in its clinical trial plans to support indication expansion of its DEXTER® Robotic Surgery System in the U.S. This announcement—focused on ventral hernia repair, sacrocolpopexy, and myomectomy clinical trials—follows recent news of the company’s completion of its hysterectomy trial and FDA clearance for use of the DEXTER system in cholecystectomy (gallbladder removal), its second U.S. indication.

Lausanne, Switzerland, June 24, 2025 (GLOBE NEWSWIRE) -- Distalmotion, a global MedTech company advancing access to robotic surgery, has reached a key milestone in its US expansion with the first multi-robot sale in the country. AdventHealth, which operates 50 hospitals in nine states, has selected the DEXTER® Robotic Surgery System to support the growth of minimally invasive surgery in its outpatient department and has already completed its first cases with the system.

Lausanne, Switzerland, May 28, 2025 (GLOBE NEWSWIRE) -- Distalmotion, the global MedTech company empowering access to the benefits of robotic surgery in more sites of care, today announced that it has received FDA 510(k) clearance for the use of its DEXTER® Robotic Surgery System in adult cholecystectomy (gallbladder removal). This milestone represents the second approved indication in the US, following De Novo clearance for inguinal hernia repair in Q4 2024.

Lausanne, Switzerland, April 22, 2025 (GLOBE NEWSWIRE) -- Distalmotion, the global MedTech company empowering access to the benefits of robotic surgery, progresses on the path to expand its US footprint with the completion of cholecystectomy and benign hysterectomy clinical trials - to support 510(k) pre-market submissions for additional indications - and product enhancements to further increase procedural fluidity and wristed instrument dexterity.

Lausanne, Switzerland, March 27, 2025 (GLOBE NEWSWIRE) -- Northtowns Ambulatory Surgery Center (ASC), a joint venture between Buffalo surgeons and Kaleida Health Ventures, has chosen Distalmotion’s DEXTER® Robotic Surgery System as its outpatient surgical robot of choice, marking a major milestone in expanding access to robotic surgery by addressing existing barriers to surgical robotics in outpatient care.

Lausanne, Switzerland, March 25, 2025 (GLOBE NEWSWIRE) -- Distalmotion announces that it completed the first US sale and delivery of the DEXTER Robotic Surgery System to Memorial Hermann Health System in Houston, Texas in early February. This milestone marks a significant step toward expanding access to robotic-assisted surgery in the United States.

Two patients were treated for inguinal hernia repair using Distalmotion’s Dexter Surgical Robot within 30 days of FDA De Novo marketing authorization.

Distalmotion’s Dexter Surgical Robot opens an entirely new era for soft tissue robotics in the outpatient setting and ambulatory surgery centers that will have immediate benefit for patients.

Lausanne, Switzerland, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Distalmotion - a pioneer in surgical robotics, is partnering with Proximie, the leading global health technology platform digitizing operating rooms (ORs), to extend its ground-breaking Dexter® robotic surgery platform globally. 

Lausanne, Switzerland, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Distalmotion, a pioneer in novel, on-demand robotics, has hired medical device industry leader, Greg Roche, as CEO. Subject to shareholder approval, Roche will also join the company’s Board of Directors. In his role, Roche will lead Distalmotion’s U.S. and EU expansion initiatives for its Dexter® surgical robot, providing experienced insight and guidance for the next phase of the company’s growth strategy.

Distalmotion announced today the closing of a USD 90 million Series E financing to support the global commercialization of its surgical robot Dexter. Revival Healthcare Capital (Revival) led the round with participation from 415 CAPITAL (415), as well as existing investors.